why choose us

First received: October 25, 2023

Clinical Trial: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Plaque Psoriasis

Study Type: INTERVENTIONAL


Official Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability

Brief Summary: The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis.Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo).Participants will be in the study for up to 69 weeks.

Read more